From Gleevec To Tasigna: Novartis' Switch Push Kicks Off With Front-Line CML Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
With its blockbuster drug Gleevec headed toward loss of exclusivity in 2015, Novartis is beginning a five-year push to switch patients to Tasigna based on positive data in first-line chronic myeloid leukemia.
You may also be interested in...
Novartis Has High Hopes For Tasigna And Predicts It Could Outpace Gleevec In CML
Novartis execs are "pleased" with Tasigna's safety profile in a head-to-head study against the more lucrative CML therapy, Gleevec.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.